Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease
The most prevalent chronic neurodegenerative illness in the world is Alzheimer’s disease (AD). It results in mental symptoms including behavioral abnormalities and cognitive impairment, which have a substantial financial and psychological impact on the relatives of the patients. The review discusses...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-10-01
|
| Series: | Molecules |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1420-3049/29/21/5131 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846173348824875008 |
|---|---|
| author | Amin Mahmood Thawabteh Aseel Wasel Ghanem Sara AbuMadi Dania Thaher Weam Jaghama Donia Karaman Rafik Karaman |
| author_facet | Amin Mahmood Thawabteh Aseel Wasel Ghanem Sara AbuMadi Dania Thaher Weam Jaghama Donia Karaman Rafik Karaman |
| author_sort | Amin Mahmood Thawabteh |
| collection | DOAJ |
| description | The most prevalent chronic neurodegenerative illness in the world is Alzheimer’s disease (AD). It results in mental symptoms including behavioral abnormalities and cognitive impairment, which have a substantial financial and psychological impact on the relatives of the patients. The review discusses various pathophysiological mechanisms contributing to AD, including amyloid beta, tau protein, inflammation, and other factors, while emphasizing the need for effective disease-modifying therapeutics that alter disease progression rather than merely alleviating symptoms. This review mainly covers medications that are now being studied in clinical trials or recently approved by the FDA that fall under the disease-modifying treatment (DMT) category, which alters the progression of the disease by targeting underlying biological mechanisms rather than merely alleviating symptoms. DMTs focus on improving patient outcomes by slowing cognitive decline, enhancing neuroprotection, and supporting neurogenesis. Additionally, the review covers amyloid-targeting therapies, tau-targeting therapies, neuroprotective therapies, and others. This evaluation specifically looked at studies on FDA-approved novel DMTs in Phase II or III development that were carried out between 2021 and 2024. A thorough review of the US government database identified clinical trials of biologics and small molecule drugs for 14 agents in Phase I, 34 in Phase II, and 11 in Phase III that might be completed by 2028. |
| format | Article |
| id | doaj-art-e4dc6dbb3db846c8be7dd5964f95db3a |
| institution | Kabale University |
| issn | 1420-3049 |
| language | English |
| publishDate | 2024-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Molecules |
| spelling | doaj-art-e4dc6dbb3db846c8be7dd5964f95db3a2024-11-08T14:38:26ZengMDPI AGMolecules1420-30492024-10-012921513110.3390/molecules29215131Recent Advances in Therapeutics for the Treatment of Alzheimer’s DiseaseAmin Mahmood Thawabteh0Aseel Wasel Ghanem1Sara AbuMadi2Dania Thaher3Weam Jaghama4Donia Karaman5Rafik Karaman6Department of Chemistry, Birzeit University, Birzeit P.O. Box 14, West Bank, PalestineFaculty of Pharmacy, Nursing and Health Professions, Birzeit University, Birzeit P.O. Box 14, West Bank, PalestineFaculty of Pharmacy, Nursing and Health Professions, Birzeit University, Birzeit P.O. Box 14, West Bank, PalestineFaculty of Pharmacy, Nursing and Health Professions, Birzeit University, Birzeit P.O. Box 14, West Bank, PalestineFaculty of Pharmacy, Nursing and Health Professions, Birzeit University, Birzeit P.O. Box 14, West Bank, PalestinePharmaceutical Sciences Department, Faculty of Pharmacy, Al-Quds University, Jerusalem 20002, PalestinePharmaceutical Sciences Department, Faculty of Pharmacy, Al-Quds University, Jerusalem 20002, PalestineThe most prevalent chronic neurodegenerative illness in the world is Alzheimer’s disease (AD). It results in mental symptoms including behavioral abnormalities and cognitive impairment, which have a substantial financial and psychological impact on the relatives of the patients. The review discusses various pathophysiological mechanisms contributing to AD, including amyloid beta, tau protein, inflammation, and other factors, while emphasizing the need for effective disease-modifying therapeutics that alter disease progression rather than merely alleviating symptoms. This review mainly covers medications that are now being studied in clinical trials or recently approved by the FDA that fall under the disease-modifying treatment (DMT) category, which alters the progression of the disease by targeting underlying biological mechanisms rather than merely alleviating symptoms. DMTs focus on improving patient outcomes by slowing cognitive decline, enhancing neuroprotection, and supporting neurogenesis. Additionally, the review covers amyloid-targeting therapies, tau-targeting therapies, neuroprotective therapies, and others. This evaluation specifically looked at studies on FDA-approved novel DMTs in Phase II or III development that were carried out between 2021 and 2024. A thorough review of the US government database identified clinical trials of biologics and small molecule drugs for 14 agents in Phase I, 34 in Phase II, and 11 in Phase III that might be completed by 2028.https://www.mdpi.com/1420-3049/29/21/5131anti-amyloid drugsaducanumablecanemabAlzheimer’s diseasechaperonesDMT |
| spellingShingle | Amin Mahmood Thawabteh Aseel Wasel Ghanem Sara AbuMadi Dania Thaher Weam Jaghama Donia Karaman Rafik Karaman Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease Molecules anti-amyloid drugs aducanumab lecanemab Alzheimer’s disease chaperones DMT |
| title | Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease |
| title_full | Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease |
| title_fullStr | Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease |
| title_full_unstemmed | Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease |
| title_short | Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease |
| title_sort | recent advances in therapeutics for the treatment of alzheimer s disease |
| topic | anti-amyloid drugs aducanumab lecanemab Alzheimer’s disease chaperones DMT |
| url | https://www.mdpi.com/1420-3049/29/21/5131 |
| work_keys_str_mv | AT aminmahmoodthawabteh recentadvancesintherapeuticsforthetreatmentofalzheimersdisease AT aseelwaselghanem recentadvancesintherapeuticsforthetreatmentofalzheimersdisease AT saraabumadi recentadvancesintherapeuticsforthetreatmentofalzheimersdisease AT daniathaher recentadvancesintherapeuticsforthetreatmentofalzheimersdisease AT weamjaghama recentadvancesintherapeuticsforthetreatmentofalzheimersdisease AT doniakaraman recentadvancesintherapeuticsforthetreatmentofalzheimersdisease AT rafikkaraman recentadvancesintherapeuticsforthetreatmentofalzheimersdisease |